Eli Lilly’s retatrutide hits Phase 3 milestone with 17% weight loss in type 2 diabetes trial
Eli Lilly and Company (NYSE:LLY) today announced positive topline results from TRANSCEND-T2D-1, the first Phase 3 clinical trial evaluating retatrutide for the treatment of type 2 diabetes.











